I

IX Biopharma Ltd
SGX:42C

Watchlist Manager
IX Biopharma Ltd
SGX:42C
Watchlist
Price: 0.119 SGD 8.18% Market Closed
Market Cap: 113.8m SGD

IX Biopharma Ltd
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

IX Biopharma Ltd
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
I
IX Biopharma Ltd
SGX:42C
Cash from Operating Activities
-S$3.8m
CAGR 3-Years
N/A
CAGR 5-Years
15%
CAGR 10-Years
N/A
WAVE Life Sciences Ltd
NASDAQ:WVE
Cash from Operating Activities
-$198m
CAGR 3-Years
-25%
CAGR 5-Years
-6%
CAGR 10-Years
-39%
Haw Par Corporation Ltd
SGX:H02
Cash from Operating Activities
S$64m
CAGR 3-Years
32%
CAGR 5-Years
-2%
CAGR 10-Years
-4%
H
Hyphens Pharma International Ltd
SGX:1J5
Cash from Operating Activities
S$7.8m
CAGR 3-Years
-1%
CAGR 5-Years
2%
CAGR 10-Years
N/A
No Stocks Found

IX Biopharma Ltd
Glance View

Market Cap
105.7m SGD
Industry
Pharmaceuticals

iX Biopharma Ltd. engages in the development and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. The firm is focused on the development and commercialization of therapies for diseases of the central nervous system using patent protected formulations for sublingual delivery. The company developed a patented drug delivery platform technology, WaferiX. WaferiX delivers drug sublingually via the mucosa for better absorption, faster onset of action and predictable effect. Its delivery platform is particularly useful for drug repurposing. The firm operates in two segments, namely Specialty Pharmaceutical and Nutraceutical segments. Specialty Pharmaceutical primary business activities are the development, manufacturing and sale of pharmaceutical and nutraceutical products. Nutraceutical primary business activities are the sale of nutraceutical products. The firm's pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management.

42C Intrinsic Value
0.033 SGD
Overvaluation 72%
Intrinsic Value
Price
I

See Also

What is IX Biopharma Ltd's Cash from Operating Activities?
Cash from Operating Activities
-3.8m SGD

Based on the financial report for Jun 30, 2025, IX Biopharma Ltd's Cash from Operating Activities amounts to -3.8m SGD.

What is IX Biopharma Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
15%

Over the last year, the Cash from Operating Activities growth was 43%.

Back to Top